Menu
Back to Journals » OncoTargets and Therapy » Volume 11
RETRACTED ARTICLE: Downregulation of ribophorin II suppresses tumor growth, migration, and invasion of nasopharyngeal carcinoma
Authors Hong F, Li Y, Ni H, Li J
Received 28 November 2017
Accepted for publication 11 March 2018
Published 15 June 2018 Volume 2018:11 Pages 3485—3494
DOI https://doi.org/10.2147/OTT.S158355
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Geoffrey Pietersz
This paper has been retracted.
Hong F, Li Y, Ni H, Li J. Onco Targets Ther. 2018;11:3485-3494.
We, the Editor and Publisher of OncoTargets and Therapy are retracting the published article. Concerns were raised following the authors request to correct images in Figure 4. It was found some of the images had been duplicated. Specifically,
- Images from Figure 4A and 4C, Migration and Invasion, siRNA, have been duplicated.
When approached for an explanation, the authors were cooperative but were unable to adequately address the concerns raised and could not provide sufficient supporting information. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The authors listed in this publication have been informed.
We have been informed in our decision-making by our editorial policies and the COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.